Genomic signatures to guide the use of chemotherapeutics

Nature Medicine

Volumn 12, Issue 11, 2006, Pages 1294-1300

  Potti, Anil ^a,b   Dressman, Holly K ^a,b   Bild, Andrea ^a,b   Riedel, Richard F ^a,b   Chan, Gina ^c   Sayer, Robyn ^c   Cragun, Janiel ^c   Cottrill, Hope ^c   Kelley, Michael J ^b   Petersen, Rebecca ^b   Harpole, David ^b   Marks, Jeffrey ^b   Berchuck, Andrew ^a,b   Ginsburg, Geoffrey S ^a,b   Febbo, Phillip ^a,b   Lancaster, Johnathan ^c   Nevins, Joseph R ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

ACCURACY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; DEREGULATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MICROARRAY ANALYSIS; OVARY CANCER; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; GENE EXPRESSION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; TAXOIDS;

EID: 33750727368     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1491     Document Type: Article

References (25)

1. Herbst, R.S. et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J. Clin. Oncol. 24, 190-205 (2006).
2. Breathnach, O.S. et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19, 1734-1742 (2001).
3. Blagosklonny, M.V. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4, 1693-1698 (2005).
4. Staunton, J.E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787-10792 (2001).
5. Chang, J.C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362-369 (2003).
6. Emi, M., Kim, R., Tanabe, K., Uchida, Y. & Toge, T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 7, R940-R952 (2005).
7. Takahashi, T. et al. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol. Cancer Ther. 4, 1039-1046 (2005).
8. Modi, S. et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 23, 483-487 (2005).
9. Langer, R. et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res. 11, 7462-7469 (2005).
10. Gyorffy, B. et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 118, 1699-1712 (2005).
11. Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
12. Rouzier, R. et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity on breast cancer. Proc. Natl. Acad. Sci. USA 102, 8315-8320 (2005).
13. DeVita, V.T., Hellman, S. & Rosenberg, S.A. Cancer: Principles and Practice of Oncology (Lippincott-Raven, Philadelphia, 2005).
14. Broxterman, H.J. & Georgopapadakou, N.H. Anticancer therapeutics: "addictive" targets, multi-targeted drugs, new drug combinations. Drug Resist. Updat. 8, 183-197 (2005).
15. Minna, J.D., Gazdar, A.F., Sprang, S.R. & Herz, J. Cancer: a bull's eye for targeted lung cancer therapy. Science 304, 1458-1461 (2004).
16. Bild, A. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353-357 (2006).
17. Vogel, C.L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-726 (2002).
18. Lugthart, S. et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7, 375-386 (2005).
19. Holleman, A. et al. Gene expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533-542 (2004).
20. Sargent, D.J., Conley, B.A., Allegra, C. & Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020-2027 (2005).
21. Pittman, J., Huang, E., Wang, Q., Nevins, J.R. & West, M. Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics 5, 587-601 (2004).
22. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207-214 (1981).
23. West, M. et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 98, 11462-11467 (2001).
24. Ihaka, R. & Gentleman, R. A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299-314 (1996).
25. Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998).